Comparative Pharmacology
Head-to-head clinical analysis: ADREVIEW versus AMINOHIPPURATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADREVIEW versus AMINOHIPPURATE SODIUM.
ADREVIEW vs AMINOHIPPURATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADREVIEW is a beta-2 adrenergic receptor agonist that stimulates cyclic AMP production, leading to bronchodilation and inhibition of mast cell mediator release.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
0.5 mg intramuscularly every 20 minutes as needed, up to 3 doses, for acute allergic reactions; or 0.1-0.5 mg subcutaneously for bronchospasm.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours; clinically relevant for dosing every 4-6 hours in renal impairment.
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
Primarily renal (80-90% as unchanged drug), with minor biliary/fecal elimination (<10%).
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
Category C
Category C
Diagnostic Agent
Diagnostic Agent